Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Overweight or Obesity: later-stage trial registry
19 of 33 indexed Overweight or Obesity trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #463 of 28,707 conditions by registered trial count.
33 US clinical trials · 19 currently recruiting · #463 of 28,707 conditions by registered trial count
Overweight or Obesity: 33 US clinical trials tracked, 19 recruiting.
Overweight or Obesity is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 8 of these trials.
Enrollment posture brief
Registry condition overweight-or-obesity
OPEN 19 | RECR 58% | LATE 8 | EARLY 5 | RANK #463 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Amputation (58% recruiting · 66 trials)
Overweight or Obesity lists 19 open slots (58% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Overweight or Obesity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Overweight or Obesity is recruiting above its size-band peers.
19 of 33 indexed trials (57.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Overweight or Obesity research.
Eli Lilly and Company accounts for 8 of 33 trials (24.2%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Overweight or Obesity enrolment sits around 200 participants.
Median target enrolment is 200 among the 33 trials that report a genuine target (sentinel values excluded). 9 of those (27.3%) plan for fewer than 100 participants.
-
Overweight or Obesity research is mostly interventional.
29 interventional and 4 observational studies make up this index (87.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
33 total, page 1 of 1
Healthy Living BEYOND Weight Study
American Heart Association
NCT07075341
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Memorial Sloan Kettering Cancer Center
NCT05770570
Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study
Duke University
NCT06596265
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Eli Lilly and Company
NCT07353931
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Eli Lilly and Company
NCT06948435
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
Wake Forest University Health Sciences
NCT05674799
eMOTION: Examining Affective Mechanisms in Physical Activity Engagement
University of Southern California
NCT06570642
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
Northwestern University
NCT04228978
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Eli Lilly and Company
NCT06864026
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
University of Chicago
NCT06499857
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Eli Lilly and Company
NCT06857942
Better Lifestyle Counseling for African American Women During Pregnancy
University of Illinois at Chicago
NCT05234125
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
Eli Lilly and Company
NCT07152002
eMOTION: Examining Implicit Attitudes in Physical Activity Engagement
University of Southern California
NCT07044570
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
BrightGene Bio-Medical Technology Co.
NCT07224399
Craving Network Neurofeedback
Yale University
NCT06426693
Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women
University of Alabama at Birmingham
NCT06360536
Postprandial Effects of Animal Versus Plant-Based Protein
Ball State University
NCT06445296
The Acute T-Rex (Timing of Resistance Exercise) Study
University of Utah
NCT06366399
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
NCT05869903
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company
NCT05803421
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
NCT06649045
Biological Sample Repository for Gastrointestinal Disorders
Pichamol Jirapinyo, MD, MPH
NCT05874726
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
Metsera, a wholly owned subsidiary of Pfizer
NCT06973720
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
Metsera, a wholly owned subsidiary of Pfizer
NCT06712836
Technology-Supported Treatment of Sleep Apnea in Prediabetes
University of Chicago
NCT04225507
Berries, Inflammation, and Gut Microbiome
Clinical Nutrition Research Center, Illinois Institute of Technology
NCT04100200
Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human
Clinical Nutrition Research Center, Illinois Institute of Technology
NCT04267705
Hepatic Energy Fluxes in NASH and NAS Patients
University of Minnesota
NCT03997422
Functional Fitness for Overweight or Obese Adults with Mobility Disabilities
University of Kansas
NCT05880966
Indigenous Supported Agriculture "Go Healthy"
Oklahoma State University Center for Health Sciences
NCT05773833
eMOTION Formative Study
University of Southern California
NCT06125964
Binge Eating Self-help for Teens ONLINE Pilot and Feasibility Study
Yale University
NCT06107387
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Overweight or Obesity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Overweight or Obesity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Overweight or Obesity page
33 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Overweight or Obesity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Overweight or Obesity trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Overweight or Obesity condition card totals 33 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.